There is currently no cure for Parkinson's disease. The symptomatic therapeutic strategy
essentially relies on dopamine replacement whose efficacy was demonstrated more than 50 …

Abstract Objective In Parkinson disease (PD), the selective C‐O‐methyltransferase (COMT)
inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by …

Congenital mirror movements (CMM) are characterized by involuntary movements of one
side of the body that mirror intentional movements on the opposite side. CMM reflect …

There is still no treatment for polyglutamine disorders, but clearance of mutant proteins might
represent a potential therapeutic strategy. Autophagy, the major pathway for organelle and …

Objective: To evaluate the efficacy and safety of zonisamide in patients with myoclonus-
dystonia. Methods: We conducted a randomized, double-blind, placebo-controlled crossover …

In the present study, we examined the potential symptomatic and/or disease-modifying
effects of monthly bee venom injections compared to placebo in moderatly affected …

Abstract Background In Parkinson's disease (PD), the response to l-dopa is highly variable
and unpredictable. The major pathway for dopamine synthesis from l-dopa is …

In Parkinson's disease, long-term dopamine replacement therapy is complicated by the
appearance of l-DOPA-induced dyskinesia (LID). One major hypothesis is that LID results …

Background Impulse control disorders are frequently associated with dopaminergic therapy
in Parkinson's disease. Genetic studies have suggested a high heritability of impulse control …

The catechol-O-methyltranferase (COMT) is one of the main enzymes that metabolise
dopamine in the brain. The Val158Met polymorphism in the COMT gene (rs4680) causes a …